Solid Biosciences wins EU orphan tag for SGT-212 in Friedreich's

Solid Biosciences has secured European Commission orphan designation for SGT-212, its dual-route gene therapy for Friedreich's ataxia, while reporting that five participants have now been dosed in the ongoing Phase 1b FALCON trial without treatment-related serious adverse events as of 5 October 2026.

The Charlestown, Massachusetts-based company said the EC acted on a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products. The designation follows a cluster of US regulatory recognitions: SGT-212 already holds FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, giving Solid a regulatory foothold on both sides of the Atlantic as it advances the programme.

The therapy and the trial

SGT-212 is a recombinant AAV-based gene replacement therapy designed to deliver the full-length frataxin gene via two concurrent routes: a precision MRI-guided infusion directly into the cerebellar dentate nuclei, followed by a systemic intravenous infusion to reach cardiomyocytes and other tissues. Frataxin deficiency disrupts mitochondrial iron handling, causing the progressive neurological deterioration and cardiac dysfunction that are the primary drivers of morbidity and mortality in FA.

FALCON is a first-in-human, open-label, multicentre Phase 1b trial evaluating safety and tolerability in adults aged 18 to 40. Solid expects to report initial clinical data in the first quarter of 2027. The topline read will be closely watched given the procedural complexity of the intradentate delivery step, which requires a stereotactic neurosurgical approach using an FDA-cleared device.

Jessie Hanrahan, Chief Regulatory and Preclinical Operations Officer at Solid Biosciences, said the designation "supports the continued development of SGT-212 globally as we advance a therapy intentionally designed for the unique challenges of FA."

Market and competitive context

Friedreich's ataxia affects around 25,000 people worldwide, classifying it firmly as a rare disease. Until recently, no approved therapy addressed the underlying frataxin deficit. Reata Pharmaceuticals' omaveloxolone, which targets downstream oxidative stress rather than the genetic root cause, received FDA approval in 2023 under the brand name Skyclarys, providing the first approved treatment for FA but leaving the gene-correction space open.

Several academic and commercial groups are pursuing frataxin gene replacement or augmentation strategies, including AAV-based approaches at preclinical and early clinical stages. Solid's dual-route design is positioned as differentiated by its simultaneous targeting of central nervous system and cardiac pathology, though the clinical validation of that mechanistic rationale remains the central question the FALCON data will need to address.

EU orphan designation carries practical benefits: ten years of market exclusivity upon approval, reduced regulatory fees, and enhanced access to scientific advice from the EMA. For a company at Phase 1b, those incentives are meaningful for capital planning and for conversations with potential commercial partners in Europe.